Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy

Parkinsonism and Related Disorders

Volumn 20, Issue 2, 2014, Pages 212-216

  Numao, Ayaka ^a   Suzuki, Keisuke ^a   Miyamoto, Masayuki ^a   Miyamoto, Tomoyuki ^a   Hirata, Koichi ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Insulin like growth factor 1; Multiple system atrophy; Parkinson's disease; Progressive supranuclear palsy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GROWTH HORMONE; LEVODOPA; QUETIAPINE; RISPERIDONE; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE DURATION; FEMALE; GROWTH HORMONE BLOOD LEVEL; HALLUCINATION; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN BLOOD LEVEL; PSYCHOSIS; RATING SCALE; SCORING SYSTEM; SHY DRAGER SYNDROME; UNIFIED MULTIPLE SYSTEM ATROPHY RATING SCALE; UNIFIED PARKINSON DISEASE RATING SCALE; VERY ELDERLY;

INSULIN-LIKE GROWTH FACTOR-1; MULTIPLE SYSTEM ATROPHY; PARKINSON'S DISEASE; PROGRESSIVE SUPRANUCLEAR PALSY;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 84893696273     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2013.11.005     Document Type: Article

References (19)

1. Benarroch E.E. Insulin-like growth factors in the brain and their potential clinical implications. Neurology 2012, 79:2148-2153.
2. Gasperi M., Castellano A.E. Growth hormone/insulin-like growth factor I axis in neurodegenerative diseases. JEndocrinol Invest 2010, 33:587-591.
3. Godau J., Herfurth M., Kattner B., Gasser T., Berg D. Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease. JNeurol Neurosurg Psychiatr 2010, 81:536-538.
4. Godau J., Knauel K., Weber K., Brockmann K., Maetzler W., Binder G., et al. Serum insulin like growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease. Arch Neurol 2011, 68:925-931.
5. Mashayekhi F., Mirzajani E., Naji M., Azari M. Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson's disease. JClin Neurosci 2010, 17:623-627.
6. Pellecchia M.T., Pivonello R., Longo K., Manfredi M., Tessitore A., Amboni M., et al. Multiple system atrophy is associated with changes in peripheral insulin-like growth factor system. Mov Disord 2010, 25:2621-2626.
7. Pellecchia M.T., Pivonello R., Salvatore E., Faggiano A., Barone P., De Michele G., et al. Growth hormone response to arginine test distinguishes multiple system atrophy from Parkinson's disease and idiopathic late-onset cerebellar ataxia. Clin Endocrinol (Oxf) 2005, 62:428-433.
8. Picillo M., Erro R., Santangelo G., Pivonello R., Longo K., Pivonello C., et al. Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naive Parkinson's disease. JNeurol 2013, 260:1724-1730.
9. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. JNeurol Neurosurg Psychiatr 1992, 55:181-184.
10. Gilman S., Wenning G.K., Low P.A., Brooks D.J., Mathias C.J., Trojanowski J.Q., et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008, 71:670-676.
11. Litvan I., Agid Y., Calne D., Campbell G., Dubois B., Duvoisin R.C., et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996, 47:1-9.
12. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967, 17:427-442.
13. Fahn S., Elton R.L. Unified Parkinson's disease rating scale. Recent development in Parkinson's disease 1987, 153-163. Members of the UPDRS Development Committee, MacMillan Health Care Information, Florham Park, NJ. S. Fahn, C.D. Marsden, M. Goldstein, D.B. Calne (Eds.).
14. Cubo E., Stebbins G.T., Golbe L.I., Nieves A., Leurgans S., Goetz C.G., et al. Application of the unified Parkinson's disease rating scale in progressive supranuclear palsy: factor analysis of the motor scale. Mov Disord 2000, 15:276-279.
15. Wenning G.K., Tison F., Seppi K., Sampaio C., Diem A., Yekhlef F., et al. Development and validation of the unified multiple system atrophy rating scale (UMSARS). Mov Disord 2004, 19:1391-1402.
16. Tomlinson C.L., Stowe R., Patel S., Rick C., Gray R., Clarke C.E. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010, 25:2649-2653.
17. Kimber J.R., Watson L., Mathias C.J. Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine. Lancet 1997, 349:1877-1881.
18. Kimber J., Mathias C.J., Lees A.J., Bleasdale-Barr K., Chang H.S., Churchyard A., et al. Physiological, pharmacological and neurohormonal assessment of autonomic function in progressive supranuclear palsy. Brain 2000, 123:1422-1430.
19. Pellecchia M.T., Santangelo G., Picillo M., Pivonello R., Longo K., Pivonello C., et al. Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naive Parkinson's disease. Eur J Neurol 2013, 10.1111/ene.12137.